Table 4.

Review of comparative studies of first-line clarithromycin-resistant H. pylori eradication therapies.

Study	VPZ-Based Regimen		PPI-Based Regimen
	Regimen	Eradication Rate	Regimen	Eradication Rate
RCT
Murakami et al., 2016 [60]	VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	82.0%	LPZ: 30 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	40.0%
Non-RCT
Noda et al., 2016 [67]	VPZ: 20 mg bid AMX: 750 mg bid CLR: 400 mg bid	87.5%	OMZ: 20 mg bid, LPZ: 30 mg bid, RPZ: 10 mg bid or ESO: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	53.8%
Matsumoto et al., 2016 [68]	VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 mg bid	76.1%	LPZ: 30 mg bid, RPZ: 10 mg bid or ESO: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	40.2%

AMX: Amoxicillin, CLR: Clarithromycin, ESO: Esomeprazole, LPZ: Lansoprazole, OMZ: Omeprazole, RPZ: Rabeprazole, VPZ: Vonoprazan.